1607486-18-9Relevant academic research and scientific papers
Benzoxazolinone aryl sulfonamides as potent, selective Nav1.7 inhibitors with in vivo efficacy in a preclinical pain model
Pero, Joseph E.,Rossi, Michael A.,Lehman, Hannah D.G.F.,Kelly, Michael J.,Mulhearn, James J.,Wolkenberg, Scott E.,Cato, Matthew J.,Clements, Michelle K.,Daley, Christopher J.,Filzen, Tracey,Finger, Eleftheria N.,Gregan, Yun,Henze, Darrell A.,Jovanovska, Aneta,Klein, Rebecca,Kraus, Richard L.,Li, Yuxing,Liang, Annie,Majercak, John M.,Panigel, Jacqueline,Urban, Mark O.,Wang, Jixin,Wang, Ying-Hong,Houghton, Andrea K.,Layton, Mark E.
supporting information, p. 2683 - 2688 (2017/05/29)
Studies on human genetics have suggested that inhibitors of the Nav1.7 voltage-gated sodium channel hold considerable promise as therapies for the treatment of chronic pain syndromes. Herein, we report novel, peripherally-restricted benzoxazoli
BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS
-
, (2014/05/24)
Disclosed are compounds of Formula A: Formula A, or a salt thereof, wherein "Het", Ra, and Rb are defined herein, which have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating neuropathic pain disorders using the same.
